Yazar "Bülbül Başkan, Emel" için listeleme
-
The efficacy and safety of omalizumab in refractory chronspontaneous urticaria: Real-life experience in Turkey
Bulur, Işıl; Bülbül Başkan, Emel; Özdemir, Mustafa; Balevi, Ali; Kocatürk Göncü, Emek; Kıvanç Altunay, İlknur; Gönül, Müzeyyen; Ergin, Can; Ertam, İlgen; Kaya Erdoǧan, Hilal; Bilgin, Muzaffer; Erdem, Mustafa Teoman (Slovenian Medical Society, 2018)Introduction: This study used real-world data to evaluate the effectiveness and reliability of omalizumab in treating recalcitrant chronic spontaneous urticaria in Turkish patients. Methods: Study data were collected ... -
Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment?
Kocatürk, Emek; Bülbül Başkan, Emel; Engin, Betül Hacer; Özdemir, Mehmet Akif; Küçük, Özlem Su; Can, Pelin; Örnek, Seçil; Hasal, Eda; Atakan, Nilgün (Wiley, 2019)... -
Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Can we define better-responding endotypes?
Kocatürk, Emek; Bülbül Başkan, Emel; Küçük, Özlem Su; Özdemir, Mustafa; Örnek, Sinem; Can, Pelin Kuteyla; Haşal, Eda; Engin, Burhan; Atakan, Nilgün; Alpsoy, Erkan (Elsevier Science Inc, 2022)Background: Chronic Spontaneous Urticaria (CSU) is characterized by recurrent wheals and/or angioedema for longer than 6-weeks. Guidelines recommend Omalizumab (Oma) as first-line and Cyclosporine-A (Cs-A) as second-line ...